In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, the authors use phosphoproteomics to define kinases with distinct activity profiles in TNBC, demonstrating their prognostic value as well as their utility for simplifying TNBC classification and designing drug regime...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-05742-z |
| id |
doaj-6508e17c6fdd4f1a8cecab535185385a |
|---|---|
| record_format |
Article |
| spelling |
doaj-6508e17c6fdd4f1a8cecab535185385a2021-05-11T10:34:01ZengNature Publishing GroupNature Communications2041-17232018-08-019111510.1038/s41467-018-05742-zIn vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerIvana Zagorac0Sara Fernandez-Gaitero1Renske Penning2Harm Post3Maria J. Bueno4Silvana Mouron5Luis Manso6Manuel M. Morente7Soledad Alonso8Violeta Serra9Javier Muñoz10Gonzalo Gómez-López11Jose Francisco Lopez-Acosta12Veronica Jimenez-Renard13Albert Gris-Oliver14Fatima Al-Shahrour15Elena Piñeiro-Yañez16Jose Luis Montoya-Suarez17Juan V. Apala18Amalia Moreno-Torres19Ramon Colomer20Ana Dopazo21Albert J. R. Heck22Maarten Altelaar23Miguel Quintela-Fandino24Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht UniversityBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht UniversityBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterMedical OncologyBiobank, CNIO – Spanish National Cancer Research CenterPathology Department, Hospital Universitario de GuadalajaraExperimental Therapeutics Group, VHIO - Vall d’Hebron Institute of OncologyProteomics Unit, CNIO – Spanish National Cancer Research CenterBioinformatics Unit, CNIO – Spanish National Cancer Research CenterBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterExperimental Therapeutics Group, VHIO - Vall d’Hebron Institute of OncologyBioinformatics Unit, CNIO – Spanish National Cancer Research CenterBioinformatics Unit, CNIO – Spanish National Cancer Research CenterMedical Oncology, Hospital Nacional Guillermo Almenara Irigoyen – ESSALUDBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterPathology Department, Hospital Universitario de FuenlabradaMedical Oncology, Hospital La PrincesaGenomics Unit, CNIC - Spanish National Center for Cardiovascular ResearchBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht UniversityBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht UniversityBreast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research CenterTriple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, the authors use phosphoproteomics to define kinases with distinct activity profiles in TNBC, demonstrating their prognostic value as well as their utility for simplifying TNBC classification and designing drug regimens.https://doi.org/10.1038/s41467-018-05742-z |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ivana Zagorac Sara Fernandez-Gaitero Renske Penning Harm Post Maria J. Bueno Silvana Mouron Luis Manso Manuel M. Morente Soledad Alonso Violeta Serra Javier Muñoz Gonzalo Gómez-López Jose Francisco Lopez-Acosta Veronica Jimenez-Renard Albert Gris-Oliver Fatima Al-Shahrour Elena Piñeiro-Yañez Jose Luis Montoya-Suarez Juan V. Apala Amalia Moreno-Torres Ramon Colomer Ana Dopazo Albert J. R. Heck Maarten Altelaar Miguel Quintela-Fandino |
| spellingShingle |
Ivana Zagorac Sara Fernandez-Gaitero Renske Penning Harm Post Maria J. Bueno Silvana Mouron Luis Manso Manuel M. Morente Soledad Alonso Violeta Serra Javier Muñoz Gonzalo Gómez-López Jose Francisco Lopez-Acosta Veronica Jimenez-Renard Albert Gris-Oliver Fatima Al-Shahrour Elena Piñeiro-Yañez Jose Luis Montoya-Suarez Juan V. Apala Amalia Moreno-Torres Ramon Colomer Ana Dopazo Albert J. R. Heck Maarten Altelaar Miguel Quintela-Fandino In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer Nature Communications |
| author_facet |
Ivana Zagorac Sara Fernandez-Gaitero Renske Penning Harm Post Maria J. Bueno Silvana Mouron Luis Manso Manuel M. Morente Soledad Alonso Violeta Serra Javier Muñoz Gonzalo Gómez-López Jose Francisco Lopez-Acosta Veronica Jimenez-Renard Albert Gris-Oliver Fatima Al-Shahrour Elena Piñeiro-Yañez Jose Luis Montoya-Suarez Juan V. Apala Amalia Moreno-Torres Ramon Colomer Ana Dopazo Albert J. R. Heck Maarten Altelaar Miguel Quintela-Fandino |
| author_sort |
Ivana Zagorac |
| title |
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| title_short |
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| title_full |
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| title_fullStr |
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| title_full_unstemmed |
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| title_sort |
in vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-08-01 |
| description |
Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, the authors use phosphoproteomics to define kinases with distinct activity profiles in TNBC, demonstrating their prognostic value as well as their utility for simplifying TNBC classification and designing drug regimens. |
| url |
https://doi.org/10.1038/s41467-018-05742-z |
| work_keys_str_mv |
AT ivanazagorac invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT sarafernandezgaitero invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT renskepenning invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT harmpost invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT mariajbueno invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT silvanamouron invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT luismanso invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT manuelmmorente invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT soledadalonso invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT violetaserra invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT javiermunoz invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT gonzalogomezlopez invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT josefranciscolopezacosta invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT veronicajimenezrenard invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT albertgrisoliver invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT fatimaalshahrour invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT elenapineiroyanez invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT joseluismontoyasuarez invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT juanvapala invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT amaliamorenotorres invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT ramoncolomer invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT anadopazo invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT albertjrheck invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT maartenaltelaar invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer AT miguelquintelafandino invivophosphoproteomicsrevealskinaseactivityprofilesthatpredicttreatmentoutcomeintriplenegativebreastcancer |
| _version_ |
1721447943913865216 |